This is the sixth issue of a monthly index of listed research peptide prices, following the May, June, July, August and September issues.
A larger share of listed prices changed in October than in any earlier month of the index, and most of the change came from four storefronts that put every listing the index tracks on sale, two of them for Halloween. Those four account for more than the index's entire net decline for the month. Elsewhere, increases outnumbered cuts: two vendors raised most of their prices, and 22 of the 39 vendors in the panel changed none.
What was measured
Prices are compared listing against listing, between the first week of October and the last. A listing counts only if it was in stock and priced in both.
- Panel: 2,183 listings, spanning 91 compounds across 39 vendors.
- Prices are the prices each storefront lists, including sale prices, before any coupon code.
- Per-milligram figures cover vial and liquid products sold by mass. Capsules, sprays and products dosed by volume are excluded.
Full definitions are on the methodology page.
Prices moved more than in any earlier month
Of the 2,183 listings, 1,626 (74%) ended October at exactly the price they started it. That is the lowest share in the six months of the index: 78% in May, 88% in June, 76% in July, 83% in August, 85% in September and 74% in October.
Among the 557 listings that did move, 406 fell and 151 rose, and the median mover fell 25%.
As of October 31, 2026, the median listed price across the compounds in the index was $4.09 per milligram, down from $4.80 at the end of September. Part of that gap is the sales described below, and part is what the index covers: it tracked 47 vendors at the end of October against 33 at the end of September. On the listings tracked at both month-ends, the median compound's price fell about 9%, most of it at the four vendors running sales. Half of all listings were priced between $2.60 and $6.69 per milligram.
Twenty-two of the 39 vendors in the panel changed no tracked price between the first week of October and the last, up from 14 of 24 in September.
Four storewide sales drove the decline
- Oneday Compounds kept up the rolling sitewide sale it has run since the summer, changing most of its prices on six dates in October. It started the month at full price and ended it at its deepest discount of the month, so all 44 of its tracked listings closed below where they began, by a median of 46%. Its 10 mg BPC-157 vial went from $49.99 to $23.99.
- ION Peptide took 25% off its whole catalog from October 8 to October 12, then 10% off from October 19, deepened to 25% on October 27. All 104 of its tracked listings ended the month at least 25% below where they started. Its storefront shows the discounts against a struck-through regular price.
- Glow Aminos ran a Halloween sale across all 86 of its tracked listings, 40% off from October 8 to October 26 and 35% off from October 28, with one day back at full price in between. Its 5 mg BPC-157 went from $29.00 to $18.85.
- Flawless Compounds ran a Halloween sale on all 85 of its tracked listings, 40% off from October 8 through October 26, then 35% off from October 28.
Together these four account for more than the index's entire net decline in October. Across the other 35 vendors in the panel, 151 listings rose and 87 fell.
Many other vendors ran Halloween promotions in late October through coupon codes and multi-buy offers. Those lower what a buyer pays at checkout and leave the listed prices this index tracks unchanged.
Cuts elsewhere were smaller
- Peptide Titans cut 27 of its 85 tracked listings on October 20 and 21, by a median of 20%, and raised two. Its 10 mg retatrutide went from $84.99 to $49.99.
- Renova Peptides cut 16 of its 50 tracked listings, most of them on October 19, by a median of 13%. The new prices are listed as regular prices.
- Optima Chemical Supply put 15 of its 67 tracked listings on sale on October 22, by a median of 14%, most of them tirzepatide, retatrutide and semaglutide.
- Glacier Aminos ran three short sales across most of its catalog, starting October 10, October 16 and October 23. Each was reversed within four days.
Three vendors raised prices
- ZC Labs raised 73 of its 82 tracked listings on October 13, by a median of 16%. Its 10 mg tirzepatide vial went from $18.99 to $24.99.
- Peppy and Me raised 38 of its 49 tracked listings, most of them on October 12, by a median of 17%. Its 10 mg ipamorelin went from $30 to $40.
- TrustedPeps reversed much of the cut it made in late September, raising 20 listings on October 4 and more on October 23.
The gap between vendors moved both ways
Among compounds carried by five or more vendors, the median one costs about four and a half times as much at its dearest listing as at its cheapest, as of October 31, 2026. That is lower than the five times reported for September because 13 more compounds now clear the five-vendor bar, and most of them sell within a narrow range. Among vendors tracked at both month-ends, the gap widened for 22 compounds, narrowed for 13 and did not change for seven.
These are the widest, as of October 31, 2026.
- 5-Amino-1MQ ranged from $0.60 to $13.80 per milligram across 64 listings from 33 vendors, the widest gap in the index. The high end is the same 5 mg vial from Licensed Peptides as in September.
- GHK-Cu ranged from $0.14 to $2.47 per milligram across 89 listings from 45 vendors.
- Retatrutide ranged from $1.00 to $17.00 per milligram across 246 listings from 46 vendors.
In all three, the cheapest listing is a ten-vial kit.
The HHS policy came at the end of the month
On October 28, 2026, the Department of Health and Human Services (HHS) filed a notice saying it does not intend to take enforcement action over the compounding of six peptides, as long as ten conditions are met. They are the six that FDA's Pharmacy Compounding Advisory Committee recommended in July: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Our analysis covers what the policy says. The notice was published on October 30, too late in the month for this issue to measure any price response.
Through October, the five of those peptides the index can measure again repriced no more often than the rest of the market: about a quarter of their 275 tracked listings changed price, the same share as everything else, and the median change was zero in both. The four-week reading after the July vote found the same.
What this does not measure
- It measures listed prices, not transaction prices. Coupons, first-order discounts and bulk terms are not applied.
- It does not test products, verify purity, or assess any vendor's certificates of analysis.
- Vendor and listing counts describe what this index covers, not the size of the market.
Sources
- PeptideScouter methodology, covering index construction, normalization and known limits.
- PeptideScouter price index, the live per-milligram figures this report is drawn from.
- Peptide Price Index, September 2026, the previous issue.
- HHS Peptide Policy: The Six Peptides and Ten Conditions, our analysis of the October 2026 enforcement discretion policy.
- Federal Register, FR Doc. 2026-22192, the HHS notice on its Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, published October 30, 2026.
- The July 2026 FDA Peptide Vote Has Not Moved Prices, the four-week reading on the recommended peptides.
- Price index data, October 2026 (CSV), covering per-compound medians, listing and vendor counts and spreads as of October 31, 2026, with the summary figures and column definitions. Every issue's files are listed at /data/price-index.
- Zenodo archive of the October 2026 files, DOI 10.5281/zenodo.23860386. The series DOI 10.5281/zenodo.22262438 resolves to the newest issue.
- Underlying data is PeptideScouter's own daily price archive, collected from public vendor storefronts.
All figures in this report are as of October 31, 2026, computed from the archive as of publication.